Antifungal efficacy of ten selected South African plant species against Cryptococcus neoformans

Pharmaceutical Biology

Volumn 48, Issue 4, 2010, Pages 397-404

  Mokoka, T A ^a   McGaw, L J ^a   Eloff, J N ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Antifungal; Bioautography; Catha transvaalensis; Cryptococcus neoformans; Fungal infections; Maytenus undata; Microdilution; Morus mesozygia; Zanthoxylum capense

Indexed keywords

ANTIFUNGAL AGENT; CALODENDRUM CAPENSE EXTRACT; CASSINE AETHIOPICA EXTRACT; CATHA TRANSVAALENSIS EXTRACT; CELTIS AFRICANA EXTRACT; CROTON SYLVATICUS EXTRACT; CUSSONIA ZULUENSIS EXTRACT; MAYTENUS UNDATA EXTRACT; MORUS MESOZYGIA EXTRACT; OCHNA NATALITIA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; ZANTHOXYLUM CAPENSE EXTRACT;

ANTIFUNGAL ACTIVITY; ARALIACEAE; ARTICLE; BROTH DILUTION; CALODENDRUM CAPENSE; CASSINE AETHIOPICA; CATHA TRANSVAALENSIS; CELASTRACEAE; CELTIS AFRICANA; CONTROLLED STUDY; CROTON SYLVATICUS; CRYPTOCOCCUS NEOFORMANS; CUSSONIA ZULUENSIS; EUPHORBIA; MAYTENUS UNDATA; MICROBIAL GROWTH; MINIMUM INHIBITORY CONCENTRATION; MORACEAE; MORUS MESOZYGIA; NONHUMAN; OCHNA NATALITIA; OCHNACEAE; PLANT LEAF; RUTACEAE; SOUTH AFRICA; ULMACEAE; ZANTHOXYLUM CAPENSE;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; MICROBIAL SENSITIVITY TESTS; PLANT EXTRACTS; PLANTS, MEDICINAL; SOLVENTS; SOUTH AFRICA;

ANIMALIA; ARALIACEAE; CALODENDRUM CAPENSE; CASSINE; CATHA; CELASTRACEAE; CELTIS AFRICANA; CUSSONIA; EUPHORBIACEAE; FILOBASIDIELLA NEOFORMANS; MAYTENUS UNDATA; MORACEAE; MORUS (PLANT); OCHNA; OCHNACEAE; RUTACEAE; ULMACEAE; ZANTHOXYLUM;

EID: 77950247519     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880200903150393     Document Type: Article

References (22)

1. Balandrin MF, Klocke JA, Wurtele ES, Bollinger WH. (1985): Natural plant chemicals: Sources of industrial and medicinal materials. Science 228: 1154-1160.
2. Beck-Sagué CM, Jarvis WR. (1993): Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 167: 1247-1251.
3. Brol CG, Cotton L, Samayoa B, Paz L, Samayoa CA, Quattrini E, Gonzalez M, Velasquez-Porta T, Arathoon E. (2002): Cryptococcus neoformans infections in persons living with HIV/AIDS that attend to urban hospitalary clinic. In: Proceedings of the International Conference on AIDS 2002, July 7-12 (14: (abstract no. B10259).
4. Cos P, Vlietinck AJ, Berghe DV, Maes L. (2006): Anti-infective potential of natural products: How to develop a stronger in vitro 'proof-ofconcept'. J Ethnopharmacol 106: 290-302.
5. Diamond RD. (1991): The growing problem of mycoses in patients infested with human immunodeficiency virus. Rev Infect Dis 13: 480-486.
6. Eloff JN. (1998a): A sensitive and quick microplate method to determine the minimum inhibitory concentration of plant extracts for bacteria. Planta Med 64: 711-713.
7. Eloff JN. (1998b): Which extractant should be used for the screening and isolation of antimicrobial components from plants? J Ethnopharmacol 60: 1-8.
8. Eloff JN. (2000): A proposal on expressing the antibacterial activity of plant extracts - a small first step in applying scientific knowledge to rural primary health care in South Africa. S Afr J Sci 96: 116-118.
9. Eloff JN. (2004): Quantification of the bioactivity of plant extracts during screening and bioassay guided fractionation. Phytomedicine 11: 370-371.
10. Gearhart MO. (1994): Worsening of lung infection with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 28: 1177-1181.
11. Ghannoum MA, Rice LB. (1999): Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501-517.
12. Goa KL, Barradell LB. (1995): Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658-690.
13. Kotzé M, Eloff JN. (2002): Extraction of antibacterial compounds from Combretum microphyllum (Combretaceae). S Afr J Bot 68: 62-67.
14. Lazar JD, Wilner KD. (1990): Drug interactions with fluconazole. Rev Infect Dis 12: 327-333.
15. Masoko P, Picard J, Eloff JN. (2005): Antifungal activities of six South African Terminalia species (Combretaceae). J Ethnopharmacol 99: 301-308.
16. Masoko P, Eloff JN. (2006): Bioautography indicates the multiplicity of antifungal compounds from twenty-four southern African Combretum species (Combretaceae). Afr J Biotechnol 5: 1625-1647.
17. McGaw LJ, Rabe T, Sparg SG, Jager AK, Eloff JN, van Staden J. (2001): An investigation on the biological activity of Combretum species. J Ethnopharmacol 75: 45-50.
18. Nostro A, Germanò MP, Angelo VD, Marino A, Cannatelli MA. (2000): Extraction methods and bioautography for evaluation of medicinal plant antimicrobial activity. Lett Appl Microbiol 30: 379-384.
19. Powderly WG. (1993): Cryptococcal meningitis and AIDS. Clin Infect Dis 17: 837-842.
20. Saral R. (1991): Candida and Aspergillus infection in immunocompromised patients: an overview. Rev Infect Dis 13: 487-492.
21. Uicker WC, Doyle HA, James PM, Langlois M, Buchanan KL. (2005): Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med Mycol 43: 27-38.
22. Van Wyk B-E, van Oudtshoorn B, Gericke N. (1997): Medicinal Plants of South Africa. Pretoria, Briza Publications, p. 10.